Healthy, Rheumatoid Arthritis
Conditions
Brief summary
This is a Phase 1, randomized, double-blind, placebo-controlled study designed in 3 parts to assess the safety, tolerability, and PK of single and multiple ascending doses of FPA008 in adult healthy volunteers (Parts 1 and 2) and adult subjects with active RA (Part 3).
Detailed description
Approximately 56 healthy volunteers will be enrolled at 1 study center in the Netherlands for Parts 1 and 2, and approximately 39 subjects will be enrolled at up to 6 sites in Central and Eastern Europe for Part 3. Dose escalations in Parts 1 and 2 will be driven by an assessment of the safety profile. Review of safety and PK parameters may inform decisions to add cohorts with intermediate dose levels in order to reach an optimal target exposure.
Interventions
DRUGFPA008
Infusion
DRUGPlacebo
Infusion
Sponsors
Five Prime Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
Part 1 and 2: * Healthy adult male and female subjects between the ages of 21-55 years inclusive. * Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of 72 hours after each dose. Part 3: * RA male and female subjects between the ages of 21-70 years inclusive * Evidence of active RA disease * Inadequate response to biologic or non-biologic DMARDs * Subjects will be required to be on background therapy with methotrexate.
Exclusion criteria
Parts 1, 2 and 3: * BMI \<18 or \>32 kg/m2 * Clinically significant findings in physical exams and laboratory tests at screening and/or baseline * Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU confinement, as applicable, and for 48 hours prior to study visits. * Unwilling to abstain from exercise more strenuous than walking during CRU confinement, as applicable, and for 48 hours prior to study visits. Parts 1 and 2: * Use of any prescription, non-prescription, or herbal medications as well as supplements or vitamins within 4 weeks prior to dosing, unless approved by the Investigator. * Smoking more than 10 cigarettes, or the equivalent, per day. Part 3: * Current or previous history of inflammatory joint disease other than RA * Evidence of extra-articular RA disease or systemic involvement * Currently taking any medications other than those allowed per protocol guidelines * Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing * Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA * Neuropathies and neurovasculopathies * Concomitant use of statins while on study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events and dose-limiting toxicities of FPA008 administered in healthy volunteers and RA subjects | within 4-12 weeks | Incidence of all-grade adverse events and dose limiting toxicities (DLT) during the DLT observation period and/or study treatment periods |
Countries
Hungary, Netherlands, Poland
Outcome results
None listed